Skip to Content

Are you based in North America? If yes, switch to our North American website →

D13S25 Deletion

Applications
haematology
Catalogue Numbers
LPH 043-S (5 tests)
LPH 043 (10 tests)

Probe Specification

  • D13S25, 13q14.3, Red
  • 13qter, 13q34, Green

The D13S25 probe, labelled in red, covers a 306kb region including most of the DLEU7 gene and the D13S25 marker. The 13qter subtelomere specific probe (clone 163C9), labelled in green, allows identification of chromosome 13 and acts as a control probe.

Probe Information

Rearrangements leading to the loss of all or part of the long arm of chromosome 13 are seen frequently in a wide range of haematological disorders.

Chromosome 13q aberrations occur in 16-40% of multiple myeloma cases (MM), most of them being complete monosomy 13 (85%), while the remaining 15% constitute deletion of 13q1.2,3. A case study of multiple myeloma patients narrowed down the critical deleted region to 13q144. Historically, deletions of 13q have been associated with poor prognosis in MM but now it is believed that its prognostic relevance may be related to its association with other concurrent genetic lesions3,5.
Deletions affecting 13q14 are also the most frequent structural genetic aberrations in chronic lymphocytic leukaemia (CLL)6,7,8. This region is found to be heterozygously deleted in 30-60% and homozygously deleted in 10-20% of CLL patients9. The survival rate has been shown to be similar for the two groups10. Patients with 13q14 deletions are classified as very low risk, in the absence of any other genetic lesions11.

Two non-coding RNA genes, DLEU1 (deleted in lymphocytic leukemia 1) and DLEU2 (deleted in lymphocytic leukemia 2), plus the genetic marker D13S319, span the pathogenic critical region of 13q1412. DLEU1 is considered to be the most likely CLL-associated candidate tumour suppressor gene within the 13q14 region13. Subsequently, D13S319, located between the RB1 gene and D13S25 and within the DLEU1 locus, was found to be deleted in 44% of CLL cases14. It has also been postulated that a gene telomeric to the D13S319 region, encompassing D13S25, may be important in cases with hemizygous deletions and that this gene is a putative tumour suppressor gene15.

Not only do Cytocell offer an extensive range of high-quality FISH probes, the customer support is also excellent — providing fast access to all the probes I need. The probes are highly consistent with bright signals allowing easy scoring of results. Dr Eric Crawford, Senior Director, Genetics Associates Inc.

References

  1. Bullrich F et al., Cancer Res 2001;61:6640-8
  2. Zojer et al., Blood 2000;95(6):1925-1930
  3. Sawyer, Cancer Genetics 2011;204:3-12
  4. Shaughnessy J et al., Blood 2000;96:1505-11
  5. Fonseca et al., Leukemia 2009;23:2210-2221
  6. Juliusson G et al., N Eng J Med 1990;323:720-4
  7. Puiggros et al., Biomed Res Int 2014;1-13
  8. Kasar et al., Nature Communications 2015;6:1-12
  9. Hammarsund M et al., FEBS Letters 2004;556:75-80
  10. Van Dyke DL et al., Br J Haematology 2009;148:544-50
  11. Rossi et al., Blood 2013;121(8):1403-1412
  12. Liu Y et al., Oncogene 1997;15:2463-73
  13. Wolf S et al., Hum Mol Genet 2001;10:1275-85
  14. Liu Y et al., Blood 1995;86:1911-5
  15. Bullrich F et al., Blood 1996;88(8):3109-15
  16. Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New Jersey: John Wiley & Sons Inc.
  17. Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.
  18. Wiktor AE, Dyke DLV, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, Dewald GW. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genetics in Medicine. 2006;8(1):16–23.

Microscope Images

D13S25 deletion magnified
Area of Interest*
CLL

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.